Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · IEX Real-Time Price · USD
16.16
-0.53 (-3.18%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Cartesian Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for RNAC stock have an average target of 42.6, with a low estimate of 39 and a high estimate of 49. The average target predicts an increase of 163.61% from the current stock price of 16.16.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RNAC stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 3 | 3 | 4 |
| Buy | 0 | 1 | 1 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 3 | 4 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $42 | Strong Buy | Reiterates | $42 | +159.90% | Jul 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $54 → $49 | Strong Buy | Maintains | $54 → $49 | +203.22% | Jul 3, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $38 → $43 | Strong Buy | Maintains | $38 → $43 | +166.09% | Jul 3, 2024 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jul 2, 2024 |
| Needham | Needham | Strong Buy Reiterates $42 | Strong Buy | Reiterates | $42 | +159.90% | Jul 1, 2024 |
Financial Forecast
Revenue This Year
16.53M
from 26.00M
Decreased by -36.45%
Revenue Next Year
15.04M
from 16.53M
Decreased by -8.96%
EPS This Year
-8.86
from -49.80
EPS Next Year
-4.93
from -8.86
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 48.4M | 52.2M | 46.7M | 30.5M | 86.1M |
| Avg | 16.5M | 15.0M | 17.5M | 9.9M | 43.1M |
| Low | 5.7M | n/a | n/a | n/a | 15.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 86.1% | 216.1% | 210.7% | 74.3% | 773.2% |
| Avg | -36.5% | -9.0% | 16.1% | -43.6% | 337.6% |
| Low | -78.1% | - | - | - | 52.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -5.35 | -2.51 | -2.51 |
| Avg | -8.86 | -4.93 | -4.55 |
| Low | -16.96 | -10.68 | -5.46 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.